1. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
   Alessia Bignucolo et al, 2017, IJMS CrossRef
2. Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer
   Min Seob Kwak et al, 2017, Medicine CrossRef
3. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care
   Marina De Rosa et al, 2016, Therap Adv Gastroenterol CrossRef
4. Drug resistance and new therapies in colorectal cancer.
   Kevin Van der Jeught et al, 2018, World J Gastroenterol CrossRef
5. Deregulation of the miR-16-KRAS axis promotes colorectal cancer
   Chaoying You et al, 2016, Sci Rep CrossRef
6. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours
   Andrew Rowland et al, 2016, European Journal of Cancer CrossRef
7. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring theKRASG13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
   Eva Segelov et al, 2016, JCO CrossRef
8. Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy.
   Mimmo Turano et al, 2019, Cancers (Basel) CrossRef
9. Complete Response With Cetuximab-Based Treatment of Metastatic Colorectal Cancers: Two Case Reports and Literature Review
   Li Wei et al, 2022, Front. Oncol. CrossRef
10. SFPQ promotes RAS-mutant cancer cell growth by modulating 5′-UTR mediated translational control of CK1α
    Venetia Jing Tong Kok et al, 2022 CrossRef
11. Study of KRAS-Related miRNA Expression in Colorectal Cancer
    Xiaobing Wu et al, 2022, CMAR CrossRef
12. RAS‐targeted cancer therapy: Advances in drugging specific mutations
    Cen Liu et al, 2023, MedComm CrossRef